A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Unresected, Stage IIIB-IV Melanoma

Trial Profile

A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Unresected, Stage IIIB-IV Melanoma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs Talimogene laherparepvec (Primary) ; Ipilimumab
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 05 Oct 2017 According to an Amgen media release, Jason Chesney is lead author of this trial.
    • 05 Oct 2017 Results published in an Amgen Media Release
    • 05 Oct 2017 Results (n=198, data cut off August 23, 2016) of primary analysis of phase II portion published in the Journal of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top